Science Sparks @ ACTREC
1st June 2026Publications
- 1. Shafiq N, Kumar A, Cherian JJ, Madan T, Kshirsagar N, Mukherjee A, Vij S, Singh PK, Srivastava G, Visala A, Kumar A, Soman A, Kotakonda HK, Joglekar S, Joshi M, Udupa V, Poomali A, Noronha NB, Gogtay N, Krishnamurthy MN, Mohapatra S, Saha N, Gota V, Pradhan AK, Chatterjee P, Kumar A, Chaturvedi A, Balasundaram MK, Prakash G, Kakkar AK, Malhotra S (2026). Regulatory and ethical frameworks for first-in-human clinical trials in India: Proceedings of a codesigned capacity-building workshop. Clinical Drug Investigation.
- 2. Singh AG, Mahajan A, Sinha S, Shetty R, Mohanty S, Kumar A, Chakrabarty N, Joshi P, Nair S, Laskar SG, Prabhash K, Chaturvedi P (2026). Tumour growth kinetics and stage progression during treatment delay in oral squamous cell carcinoma. Oral Oncology.
- 3. Juneja A, Sahay A, Padwale P, Patil A, Pai T, Panjwani P, Joshi S, Wadasadawala T, Popat P, Shet TM, Gupta S, Desai SB (2026). Concordance of conventional two-tier HER2 classification versus three-tier classification (including HER2-low status) in invasive breast carcinoma: a retrospective real-world analysis. Journal of Clinical Pathology.
- 4. Shinde P, Ak A, Agarwal P, Kamalnath J, Joshi K, Prajapati K, Jain J, Mulani J, Gupta A, Mittal P, Sawant P, Agarwal JP, Cozzi L, Chopra S (2026). Spatially fractionated radiotherapy using straight and bending virtual rods as an alternative for cervical cancer brachytherapy-results from preclinical in-silico dose comparison and quality assurance. British Journal of Radiology.
- 5. Sakhare N, Muralidharan S, Kumar D, Dutta S, Gnanasekar R, Paradkar S, Mitra A, Mohanty B, Mirapurkar A, Mathur A, Chaudhari P, Bose K (2026). Synthesis and evaluation of 99mTc essential analogue of DUPA PSMA inhibitor for its potential use in prostate cancer imaging. ChemistrySelect. 11(21): e06967.
- 6. Noguera NI, Hasan SK and Cicconi L (2026) Evaluating differentiation therapy and biomarkers in myeloid malignancies. Frontiers in Oncology. 16:1867602.
- 7. Dey S, Anne S, Rath S, Nandhana R, Gulia S, Dash B, Menon S, Rekhi B, Baheti A, Sable N, Popat P, Tandon S, Ghosh K, Gurram L, Parab SS, Logkumer AN, Jhadhav S, Chopra S, Surappa ST, Bansal V, Balsarkar G, Deodhar K, Maheshwari A, Ghosh J, Gupta S (2026). Malignant ovarian germ cell tumor-survival and reproductive outcomes and patterns of relapse. Cancer Medicine. 15(6):e71936.
Video of the Week
The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations
Upcoming Events
June 15-17, 2026
At ACTREC, Tata Memorial Centre
June 25-27, 2026
Online Workshop, by ACTREC, Tata Memorial Centre
Do You Know?
In 1915, Katsusaburo Yamagiwa and Koichi Ichikawa induced cancer in rabbits by applying coal tar to their skin, providing experimental proof that chemicals can cause cancer.
Cancer News
News-Medical.Net, 26/05/2026
The researchers emphasize that the model was designed not only to make predictions, but also to provide insight into why those predictions are made, which could help when refining biomarkers and treatment strategies...
Oncology News Central, 28/05/2026
Sthe U.S. Food and Drug Administration (FDA) approved pivekimab sunirine-pvzy (Decnupaz) for adults with the rare hematologic malignancy blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive hematologic malignancy with historically limited treatment options...
EurekAlert, 28/05/2026
In this study, the research team developed scalable artificial intelligence (AI) frameworks to detect, profile and classify TLSs from spatial omics data and routine pathology slides. They also created a composite scoring system to more effectively stratify patients by prognosis and treatment response across different...
© 2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)